1788P Association between deep prostate-specific antigen decline and survival in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial.

Authors :: Chang, K.
Zhang, X.
Xie, L.
Wang, S.
Shi, B.
Sun, T.
Wei, S.
Weng, Z.
Xia, S.
Han, B.
Xu, Z.
Xing, J.
Zhang, D.
Xu, D.
Du, C.
He, C.
Wang, Q.
Lian, J.
Shi, Q.
Ye, D.
Source :: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS966-S967. 2p.
Publication Year :: 2023

Subjects :: *PROSTATE-specific antigen
*OVERALL survival
*PROSTATE cancer
*METASTASIS

Full Text Access

Tools